Vimarsana
Biggest News Aggregation in the World

Page 2 - Safer Technologies Program Ste News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safer Technologies Program Ste. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safer Technologies Program Ste Today - Breaking & Trending Today

2022 Life Sciences and Health Care Horizons - Vimarsana News

2022 Life Sciences and Health Care Horizons

We increasingly encounter research and Development collaboration partners relying On various research tools, cell lines, and other Technologies to…

ProximaCRO: Proxima Clinical Research Client, Airway Shield, Receives STeP Designation for Endotracheal Intubation Device that Protects Patients and Clinicians - Vimarsana News

ProximaCRO: Proxima Clinical Research Client, Airway Shield, Receives STeP Designation for Endotracheal Intubation Device that Protects Patients and Clinicians

Device reduces the spread of infection from patients to clinicians during aerosol generating procedures like intubation of COVID-19 patients, among othersHOUSTON, TX / ACCESSWIRE / May 18, 2022 / Proxima

Pear Therapeutics Reports First Quarter 2022 Financial Results - Vimarsana News

Pear Therapeutics Reports First Quarter 2022 Financial Results

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Brightline launches autism care program for caregivers and more digital health briefs - Vimarsana News

Brightline launches autism care program for caregivers and more digital health briefs

Also: Pear Therapeutics receives FDA SteP designation for its product candidate focused on acute and chronic pain, and Carbon Health launches its diabetes management program.

FDA grants STeP designation for Pear Therapeutics' neurobehavioral digital therapeutic - Vimarsana News

FDA grants STeP designation for Pear Therapeutics' neurobehavioral digital therapeutic

Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate.